The scope of use for the prostate cancer treatment Xtandi soft capsule (enzalutamide, Astellas Korea) will be expanded. Although the drug was applied reimbursement only when other drugs that suppress androgen production cannot be used, reimbursement will be applied regardless of such status starting next month.

On the 18th, the Health Insurance Review and Assessment service prepared an amendment to the anticancer drug reimbursement standards that contained the changes above and started reviewing industry opinion.

Under the proposed amendment, the reimbursement condition, ‘when other drugs that suppress androgen production cannot be used,' will be deleted from the standards for Xtandi’